Table 5.
Oncological Drugs by Antithrombotic Therapy Before Admission/Consultation
| No AT/AC Therapy at Study Entry (n = 252) | AT/AC Therapy at Study Entry (n = 1,262) | |
|---|---|---|
| Anthracycline and analogues | 23 (9.1) | 117 (9.3) |
| Nonanthracycline chemotherapy | 117 (46.4) | 632 (50.1) |
| Other antitumor antibiotics | 2 (0.8) | 20 (1.6) |
| Topoisomerase inhibitors | 10 (4.0) | 34 (2.7) |
| Alkylating agents | 54 (21.4) | 283 (22.4) |
| Antimetabolites | 44 (17.5) | 208 (16.5) |
| Microtubule targeting agents (vinca alkaloids) | 6 (2.4) | 64 (5.1) |
| Taxane derivative | 26 (10.3) | 95 (7.5) |
| Monoclonal antibodies | 25 (9.9) | 157 (12.4) |
| Multi-targeted tyrosine kinase inhibitors (TKIs) | 21 (8.3) | 107 (8.5) |
| Biological response modifiers and differentiation agents | 1 (0.4) | 7 (0.6) |
| Proteasome inhibitors | 1 (0.4) | 27 (2.1) |
| Histone deacetylase inhibitors (HDAC-I) | - | - |
| Immune checkpoint inhibitors (ICIs) [CTLA4/PD-1/PD-L1] | 19 (7.5) | 65 (5.2) |
Values are n (%).
AC = anticoagulant; AT = antithrombotic.